Anaptysbio Inc (ANAB) 13F Investor Activity Report (Q2 2026)

ANAB ranks #2818 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ANAB is a top-conviction position for EcoR1 Capital, LLC — at 25.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

EcoR1 Capital, LLC has added to its ANAB position for two straight quarters, increasing it by $149.9M to reach $531.9M today.

Jane Street Group, LLC has trimmed its ANAB position for two straight quarters, cutting it by $10.1M while still holding $209.3K.

ANAB is up 1% today, and institutions have been net buyers of $272.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ANAB reported a net loss of $26.8M over the trailing twelve months.

• Not yet profitable — net loss of $26.8M over the trailing twelve months
• Revenue grew 107.7% year over year
• Net income improved year over year, from -$140.6M to -$26.8M
• Generated $19.7M in positive operating cash flow
• Current ratio of 9.07x — enough short-term assets to cover short-term liabilities
• Liabilities run 9.79x equity — a highly leveraged balance sheet worth noting